Free Trial

Fmr LLC Sells 825,251 Shares of Afya Limited (NASDAQ:AFYA)

Afya logo with Consumer Discretionary background

FMR LLC trimmed its stake in shares of Afya Limited (NASDAQ:AFYA - Free Report) by 24.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,612,538 shares of the company's stock after selling 825,251 shares during the period. FMR LLC owned approximately 2.79% of Afya worth $44,596,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Renaissance Technologies LLC raised its stake in shares of Afya by 19.7% during the second quarter. Renaissance Technologies LLC now owns 266,500 shares of the company's stock worth $4,704,000 after buying an additional 43,800 shares during the last quarter. Millennium Management LLC boosted its holdings in Afya by 45.0% during the second quarter. Millennium Management LLC now owns 291,164 shares of the company's stock worth $5,139,000 after purchasing an additional 90,383 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Afya by 136.9% during the second quarter. Cubist Systematic Strategies LLC now owns 35,254 shares of the company's stock worth $622,000 after purchasing an additional 20,370 shares during the last quarter. Marshall Wace LLP boosted its holdings in Afya by 41.8% during the second quarter. Marshall Wace LLP now owns 336,985 shares of the company's stock worth $5,948,000 after purchasing an additional 99,416 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in Afya during the third quarter worth $417,000. 88.02% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. UBS Group assumed coverage on shares of Afya in a research note on Friday, August 30th. They issued a "neutral" rating and a $19.50 price target for the company. The Goldman Sachs Group assumed coverage on shares of Afya in a research note on Tuesday, December 3rd. They issued a "sell" rating and a $16.00 price target for the company.

Check Out Our Latest Analysis on AFYA

Afya Stock Performance

Shares of AFYA traded down $0.29 during trading hours on Friday, hitting $16.11. The company had a trading volume of 134,298 shares, compared to its average volume of 121,400. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of 12.99, a PEG ratio of 0.33 and a beta of 0.89. The business has a fifty day moving average of $16.76 and a 200-day moving average of $17.05. Afya Limited has a 12 month low of $15.28 and a 12 month high of $22.48. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 0.51.

Afya Company Profile

(Free Report)

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.

Featured Stories

Institutional Ownership by Quarter for Afya (NASDAQ:AFYA)

→ ⭕ [URGENT] Buy Alert just triggered (From Behind the Markets) (Ad)

Should you invest $1,000 in Afya right now?

Before you consider Afya, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Afya wasn't on the list.

While Afya currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines